Further investigation of TRAIL-sensitive tumor types and identification of important biomarkers that would predict either TRAIL sensitivity or resistance may be critical for optimizing the clinical efficacy of TRAIL-Trimer therapy40. This evidence concerns the gene TNFSF10 and neoplasm.